potential for cell damage due to high local drug concentrations.
2
. Autologous hematopoietic stem cells were reinfused 48 h after completion of the conditioning regimen. Oral mucositis and enteritis are dose-limiting toxicities of high-dose etoposide regimens supported with hematopoAnticholinergic regimen ietic stem cells. [1] [2] [3] The addition of other chemotherapeutic agents or of irradiation may worsen the mucosal damage. 4 Propantheline 15 mg was administered every 6 h by mouth Local therapy with sucralfate slurries offers modest protecstarting with initiation of the conditioning regimen and tion for the oral mucosa.
5 Systemic therapy with an oral stopping 24 h after completion of the etoposide infusion. anticholinergic drug, propantheline, has reduced the severWe changed the propantheline dose to 30 mg every 6 h ity of oral mucositis associated with a 24 h infusion of etowhen a patient developed grade III oral mucositis and never poside at a dose of 1800 mg/m 2 . 6 The rationale for this reported symptoms of a dry mouth. treatment is the excretion of etoposide in saliva and the The incidence of severe non-oral GI toxicity was very obtain routine viral surveillance cultures for herpes virus, high. All patients required systemic narcotics, primarily for but did perform diagnostic cultures on patients with severe esophageal pain and/or hyperalimentation for negligible stomatitis, delayed healing or worsening stomatitis after oral intake. There was no evidence for a protective effect initial healing.
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of propantheline for the esophagitis and enteritis associated with the ICE regimen. We performed upper endoscopy on three patients with mild mucositis but severe esophageal Grading of mucositis pain. In each case there was esophageal and gastric mucosTwo observers assessed the oral cavity daily. Toxicity graditis consistent with a chemotherapy effect. We never docuing followed the WHO criteria. The term 'mild' mucositis mented other etiologies for the findings, such as viral or indicates WHO grades 0, I and II, and 'severe' grades fungal infections. The clinical picture of mild oral mucositis III-IV.
and esophageal pain and/or enteritis was so consistent that we discontinued endoscopic evaluations in this clinical setting.
Results
The toxicity of propantheline was modest and manageable. Side-effects included tachycardia, urinary retention, Table 1 outlines the patient characteristics of the 31 conand constipation. Unexplained asymptomatic tachycardia secutive patients who entered the trial. Table 2 shows the was common. One patient developed symptomatic palpi-WHO grade of oral mucositis. The table includes data from tations for which the medication was discontinued. One patients treated by Fields et al 8 and conditioned with the patient developed the acute onset of urinary retention after ICE regimen with the same chemotherapy drug dosages and the first dose of propantheline 30 mg. Her symptoms schedules used in our protocol.
resolved spontaneously, and she tolerated a reduced dose In our study 28 of 31 (90%; 95% CI 74-98%) patients of 15 mg of propantheline without further toxicity. She was had mild oral mucositis. Within this group, three patients the only one of the 31 patients to experience urinary retenhad no evidence of oral mucositis. Sixteen (52%) patients tion. Six patients complained of transient constipation. 
Discussion
would justify proceeding to a randomized placebo-controlled trial. The very dramatic shift from a predominance of severe oral mucositis without propantheline in our small historical experience and in the reference group to a preOur study demonstrates that prolonged administration of dominance of mild mucositis in our study patients was an propantheline is safe and that anticholinergic therapy has a unexpected finding. We feel that the low toxicity profile major protective effect upon oral mucosa after high-dose and the high level of efficacy make a randomized, placebo-ICE chemotherapy. Etoposide is the drug which is responcontrolled trial unnecessary. Propantheline should be consible for most of the mucositis.
1-3 Since etoposide is sidered as a supportive care measure in etoposidesecreted in saliva, the high local drug concentrations containing regimens which may cause oral mucositis. augment the oral toxicity.
2,3,7 Propantheline reduces the production of saliva and reduces the direct presentation of etoposide to the mucosal lining of the mouth.
Dose escalation of etoposide in conditioning regimens has been limited to the range of 1.5 g/m 2 of body surface References area due to severe mucositis. Ahmed et al have reported less mucositis with propantheline after a 1-day infusion of etoposide at 1800 mg/m 2 . Data with higher doses and more Our study was a phase II design to determine the safety 4330-4331. and efficacy of propantheline administered over 7 days. We cystitis. Our primary endpoint was a safety profile that
